[SCHEDULE 13G/A] Kura Oncology, Inc. SEC Filing
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly reported beneficial ownership of Kura Oncology common stock on a Schedule 13G/A. EcoR1 and Mr. Nodelman each report shared voting and shared dispositive power over 4,200,000 shares, representing 4.8% of the outstanding common stock, while the Qualified Fund reports shared voting and dispositive power over 3,937,232 shares, representing 4.5%.
The filing states these interests were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer. The filing also discloses that EcoR1 is the general partner and investment adviser to funds including the Qualified Fund and that Mr. Nodelman is the control person of EcoR1. Percentages are calculated using 86,797,185 shares outstanding as reported in the issuer's quarter-end filing.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. e Oleg Nodelman hanno comunicato congiuntamente la titolarit脿 economica delle azioni ordinarie di Kura Oncology in un Schedule 13G/A. EcoR1 e il Sig. Nodelman dichiarano ciascuno di detenere in comune il potere di voto e il potere dispositive su 4,200,000 azioni, pari al 4,8% del capitale sociale in circolazione, mentre il Qualified Fund dichiara potere di voto e di disposizione condivisi su 3,937,232 azioni, pari al 4,5%.
Il deposito specifica che tali partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non sono state acquistate per influenzare il controllo dell'emittente. Viene inoltre indicato che EcoR1 猫 il socio accomandatario e consulente per gli investimenti di fondi, incluso il Qualified Fund, e che il Sig. Nodelman 猫 la persona di controllo di EcoR1. Le percentuali sono calcolate sulla base di 86,797,185 azioni in circolazione, come riportato nella comunicazione di fine trimestre dell'emittente.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. y Oleg Nodelman informaron conjuntamente la titularidad beneficiaria de acciones ordinarias de Kura Oncology mediante un Schedule 13G/A. EcoR1 y el Sr. Nodelman declaran cada uno tener poder de voto compartido y poder dispositvo compartido sobre 4,200,000 acciones, que representan el 4,8% del capital en circulaci贸n, mientras que el Qualified Fund declara poder de voto y de disposici贸n compartidos sobre 3,937,232 acciones, que representan el 4,5%.
La presentaci贸n se帽ala que estas participaciones se adquirieron y se mantienen en el curso ordinario del negocio y no se adquirieron para influir en el control del emisor. Tambi茅n revela que EcoR1 es el socio general y asesor de inversiones de fondos, incluido el Qualified Fund, y que el Sr. Nodelman es la persona de control de EcoR1. Los porcentajes se calculan sobre la base de 86,797,185 acciones en circulaci贸n, seg煤n consta en la presentaci贸n trimestral del emisor.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. 氚� Oleg Nodelman鞚� Schedule 13G/A毳� 韱淀暣 Kura Oncology 氤错喌欤检潣 鞁れ鞝� 靻岇湢甓岇潉 瓿惦彊 氤搓碃頄堨姷雼堧嫟. EcoR1瓿� Nodelman 鞌姅 臧侁皝 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 4,200,000欤�鞐� 雽�頃� 氤搓碃頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 4.8%鞐� 頃措嫻頃╇媹雼�. Qualified Fund電� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 3,937,232欤�鞐� 雽�頃� 氤搓碃頄堨溂氅�, 鞚措姅 4.5%鞐� 頃措嫻頃╇媹雼�.
鞁犼碃靹滌棎電� 鞚措煬頃� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 旆摑霅橃柎 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 頇曤炒頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞁犼碃靹滌棎電� EcoR1鞚� Qualified Fund毳� 韽暔頃� 韼�霌滊摛鞚� 齑濌磩毂呾瀯鞛�(General Partner)鞚挫瀽 韴瀽鞛愲靷�(Investment Adviser)鞚措┌, Nodelman 鞌皜 EcoR1鞚� 歆�氚办澑(control person)鞚措澕瓿� 氚濏榾鞝� 鞛堨姷雼堧嫟. 牍勳湪鞚� 氚滍枆鞚胳澊 攵勱赴毵� 鞝滌稖靹滌棎 氤搓碃頃� 86,797,185欤检潣 氚滍枆欤检嫕鞚� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. et Oleg Nodelman ont d茅clar茅 conjointement la d茅tention effective d'actions ordinaires de Kura Oncology dans un Schedule 13G/A. EcoR1 et M. Nodelman d茅clarent chacun d茅tenir conjointement le pouvoir de vote et le pouvoir de disposition sur 4,200,000 actions, repr茅sentant 4,8% du capital social en circulation, tandis que le Qualified Fund d茅clare d茅tenir conjointement le pouvoir de vote et de disposition sur 3,937,232 actions, soit 4,5%.
Le d茅p么t indique que ces participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et n'ont pas 茅t茅 acquises dans le but d'influencer le contr么le de l'茅metteur. Il pr茅cise 茅galement qu'EcoR1 est l'associ茅 commandit茅 et le conseiller en investissement de fonds, y compris le Qualified Fund, et que M. Nodelman est la personne de contr么le d'EcoR1. Les pourcentages sont calcul茅s sur la base de 86,797,185 actions en circulation, comme indiqu茅 dans le d茅p么t de fin de trimestre de l'茅metteur.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. und Oleg Nodelman meldeten gemeinsam die wirtschaftliche Eigent眉merschaft an Stammaktien von Kura Oncology in einem Schedule 13G/A. EcoR1 und Herr Nodelman geben jeweils gemeinsame Stimmrechte und gemeinsames Verf眉gungsrecht 眉ber 4,200,000 Aktien an, was 4,8% des ausstehenden Stammkapitals entspricht, w盲hrend der Qualified Fund gemeinsame Stimm- und Verf眉gungsrechte 眉ber 3,937,232 Aktien meldet, entsprechend 4,5%.
Die Einreichung besagt, dass diese Beteiligungen im gew枚hnlichen Gesch盲ftsgang erworben und gehalten werden und nicht zum Zweck der Erlangung der Kontrolle 眉ber den Emittenten erworben wurden. Weiter wird offengelegt, dass EcoR1 der Generalpartner und Anlageberater von Fonds, einschlie脽lich des Qualified Fund, ist und dass Herr Nodelman die kontrollierende Person von EcoR1 ist. Die Prozents盲tze basieren auf 86,797,185 ausstehenden Aktien, wie in der Quartalsmeldung des Emittenten angegeben.
- None.
- None.
Insights
TL;DR: Passive institutional disclosure; stakes are material for monitoring but below 5%, suggesting no immediate control intent.
The Schedule 13G/A shows coordinated, transparent disclosure of positions by EcoR1, its Qualified Fund, and Oleg Nodelman. Each reporting person indicates shared voting and dispositive power rather than sole control, and percentages (4.8% and 4.5%) are calculated on an 86.8 million share base from the issuer filing. The certification that holdings are in the ordinary course and not for control reduces immediate governance risk. For investors, this is a signal of institutional interest without an activist control effort.
TL;DR: Joint filing with disclaimers limits group inference; governance impact appears limited given stated intent and sub-5% stakes.
The filing explicitly disclaims group membership while filing jointly and records EcoR1 as general partner/adviser and Mr. Nodelman as its control person. Reported positions show no sole voting or dispositive power and the signatories certify the securities were not acquired to influence control. From a governance perspective, the disclosure improves transparency but, based on the facts provided, does not indicate an imminent change in corporate control or board pressure.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. e Oleg Nodelman hanno comunicato congiuntamente la titolarit脿 economica delle azioni ordinarie di Kura Oncology in un Schedule 13G/A. EcoR1 e il Sig. Nodelman dichiarano ciascuno di detenere in comune il potere di voto e il potere dispositive su 4,200,000 azioni, pari al 4,8% del capitale sociale in circolazione, mentre il Qualified Fund dichiara potere di voto e di disposizione condivisi su 3,937,232 azioni, pari al 4,5%.
Il deposito specifica che tali partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non sono state acquistate per influenzare il controllo dell'emittente. Viene inoltre indicato che EcoR1 猫 il socio accomandatario e consulente per gli investimenti di fondi, incluso il Qualified Fund, e che il Sig. Nodelman 猫 la persona di controllo di EcoR1. Le percentuali sono calcolate sulla base di 86,797,185 azioni in circolazione, come riportato nella comunicazione di fine trimestre dell'emittente.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. y Oleg Nodelman informaron conjuntamente la titularidad beneficiaria de acciones ordinarias de Kura Oncology mediante un Schedule 13G/A. EcoR1 y el Sr. Nodelman declaran cada uno tener poder de voto compartido y poder dispositvo compartido sobre 4,200,000 acciones, que representan el 4,8% del capital en circulaci贸n, mientras que el Qualified Fund declara poder de voto y de disposici贸n compartidos sobre 3,937,232 acciones, que representan el 4,5%.
La presentaci贸n se帽ala que estas participaciones se adquirieron y se mantienen en el curso ordinario del negocio y no se adquirieron para influir en el control del emisor. Tambi茅n revela que EcoR1 es el socio general y asesor de inversiones de fondos, incluido el Qualified Fund, y que el Sr. Nodelman es la persona de control de EcoR1. Los porcentajes se calculan sobre la base de 86,797,185 acciones en circulaci贸n, seg煤n consta en la presentaci贸n trimestral del emisor.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. 氚� Oleg Nodelman鞚� Schedule 13G/A毳� 韱淀暣 Kura Oncology 氤错喌欤检潣 鞁れ鞝� 靻岇湢甓岇潉 瓿惦彊 氤搓碃頄堨姷雼堧嫟. EcoR1瓿� Nodelman 鞌姅 臧侁皝 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 4,200,000欤�鞐� 雽�頃� 氤搓碃頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 4.8%鞐� 頃措嫻頃╇媹雼�. Qualified Fund電� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 3,937,232欤�鞐� 雽�頃� 氤搓碃頄堨溂氅�, 鞚措姅 4.5%鞐� 頃措嫻頃╇媹雼�.
鞁犼碃靹滌棎電� 鞚措煬頃� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 旆摑霅橃柎 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 頇曤炒頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞁犼碃靹滌棎電� EcoR1鞚� Qualified Fund毳� 韽暔頃� 韼�霌滊摛鞚� 齑濌磩毂呾瀯鞛�(General Partner)鞚挫瀽 韴瀽鞛愲靷�(Investment Adviser)鞚措┌, Nodelman 鞌皜 EcoR1鞚� 歆�氚办澑(control person)鞚措澕瓿� 氚濏榾鞝� 鞛堨姷雼堧嫟. 牍勳湪鞚� 氚滍枆鞚胳澊 攵勱赴毵� 鞝滌稖靹滌棎 氤搓碃頃� 86,797,185欤检潣 氚滍枆欤检嫕鞚� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. et Oleg Nodelman ont d茅clar茅 conjointement la d茅tention effective d'actions ordinaires de Kura Oncology dans un Schedule 13G/A. EcoR1 et M. Nodelman d茅clarent chacun d茅tenir conjointement le pouvoir de vote et le pouvoir de disposition sur 4,200,000 actions, repr茅sentant 4,8% du capital social en circulation, tandis que le Qualified Fund d茅clare d茅tenir conjointement le pouvoir de vote et de disposition sur 3,937,232 actions, soit 4,5%.
Le d茅p么t indique que ces participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et n'ont pas 茅t茅 acquises dans le but d'influencer le contr么le de l'茅metteur. Il pr茅cise 茅galement qu'EcoR1 est l'associ茅 commandit茅 et le conseiller en investissement de fonds, y compris le Qualified Fund, et que M. Nodelman est la personne de contr么le d'EcoR1. Les pourcentages sont calcul茅s sur la base de 86,797,185 actions en circulation, comme indiqu茅 dans le d茅p么t de fin de trimestre de l'茅metteur.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. und Oleg Nodelman meldeten gemeinsam die wirtschaftliche Eigent眉merschaft an Stammaktien von Kura Oncology in einem Schedule 13G/A. EcoR1 und Herr Nodelman geben jeweils gemeinsame Stimmrechte und gemeinsames Verf眉gungsrecht 眉ber 4,200,000 Aktien an, was 4,8% des ausstehenden Stammkapitals entspricht, w盲hrend der Qualified Fund gemeinsame Stimm- und Verf眉gungsrechte 眉ber 3,937,232 Aktien meldet, entsprechend 4,5%.
Die Einreichung besagt, dass diese Beteiligungen im gew枚hnlichen Gesch盲ftsgang erworben und gehalten werden und nicht zum Zweck der Erlangung der Kontrolle 眉ber den Emittenten erworben wurden. Weiter wird offengelegt, dass EcoR1 der Generalpartner und Anlageberater von Fonds, einschlie脽lich des Qualified Fund, ist und dass Herr Nodelman die kontrollierende Person von EcoR1 ist. Die Prozents盲tze basieren auf 86,797,185 ausstehenden Aktien, wie in der Quartalsmeldung des Emittenten angegeben.
FAQ
What stake did EcoR1 Capital report in KURA?
What stake did EcoR1 Capital Fund Qualified, L.P. report in KURA?
Does any reporting person have sole voting or dispositive power?
Did the filing state an intent to influence control of KURA?
What share count was used to calculate the percentages?
